Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
$38.46
-1.7%
$39.79
$29.85
$45.00
$4.89B1.251.24 million shs693,348 shs
HealthEquity, Inc. stock logo
HQY
HealthEquity
$79.04
-0.2%
$81.08
$48.86
$84.49
$6.78B0.53600,952 shs596,788 shs
MultiPlan Co. stock logo
MPLN
MultiPlan
$0.57
-1.9%
$0.88
$0.54
$2.29
$367.81M0.61.65 million shs1.99 million shs
Nutex Health Inc. stock logo
NUTX
Nutex Health
$0.65
-2.5%
$1.37
$0.50
$9.30
$32.46M0.44240,932 shs184,301 shs
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
+0.38%+2.89%-3.22%+13.36%+16.53%
HealthEquity, Inc. stock logo
HQY
HealthEquity
-0.84%-0.84%-0.23%+2.43%+48.12%
MultiPlan Co. stock logo
MPLN
MultiPlan
+3.30%-19.78%-28.43%-42.96%-39.35%
Nutex Health Inc. stock logo
NUTX
Nutex Health
+0.48%+1.13%-56.85%-67.40%-92.03%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
4.8933 of 5 stars
3.41.00.04.42.82.54.4
HealthEquity, Inc. stock logo
HQY
HealthEquity
3.8405 of 5 stars
3.52.00.00.02.92.53.1
MultiPlan Co. stock logo
MPLN
MultiPlan
0.3986 of 5 stars
2.01.00.00.01.41.70.6
Nutex Health Inc. stock logo
NUTX
Nutex Health
2.456 of 5 stars
3.55.00.00.00.61.70.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
2.86
Moderate Buy$53.2938.55% Upside
HealthEquity, Inc. stock logo
HQY
HealthEquity
3.00
Buy$96.1721.67% Upside
MultiPlan Co. stock logo
MPLN
MultiPlan
N/AN/A$2.00250.39% Upside
Nutex Health Inc. stock logo
NUTX
Nutex Health
3.00
Buy$15.002,197.44% Upside

Current Analyst Ratings

Latest HQY, MPLN, NUTX, and HALO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/17/2024
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$50.00
4/16/2024
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$50.00
4/4/2024
HealthEquity, Inc. stock logo
HQY
HealthEquity
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageMkt Outperform$101.00
4/2/2024
HealthEquity, Inc. stock logo
HQY
HealthEquity
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$86.00 ➝ $108.00
3/22/2024
HealthEquity, Inc. stock logo
HQY
HealthEquity
KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$85.00 ➝ $95.00
3/22/2024
HealthEquity, Inc. stock logo
HQY
HealthEquity
Barrington Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$100.00
3/20/2024
HealthEquity, Inc. stock logo
HQY
HealthEquity
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$100.00 ➝ $110.00
3/20/2024
HealthEquity, Inc. stock logo
HQY
HealthEquity
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$90.00 ➝ $92.00
3/20/2024
HealthEquity, Inc. stock logo
HQY
HealthEquity
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$93.00 ➝ $97.00
2/29/2024
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$54.00
2/23/2024
HealthEquity, Inc. stock logo
HQY
HealthEquity
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$77.00 ➝ $90.00
(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
$829.25M5.89$3.14 per share12.26$0.63 per share61.05
HealthEquity, Inc. stock logo
HQY
HealthEquity
$999.59M6.78$3.38 per share23.36$23.72 per share3.33
MultiPlan Co. stock logo
MPLN
MultiPlan
$961.52M0.38$0.46 per share1.25$2.64 per share0.22
Nutex Health Inc. stock logo
NUTX
Nutex Health
$247.65M0.13N/AN/A$1.77 per share0.37

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
$281.59M$2.1118.239.010.4533.96%248.20%19.13%5/7/2024 (Confirmed)
HealthEquity, Inc. stock logo
HQY
HealthEquity
$55.71M$0.64123.5028.331.305.57%6.91%4.41%6/3/2024 (Estimated)
MultiPlan Co. stock logo
MPLN
MultiPlan
-$91.70M-$0.15N/AN/A-9.54%-8.31%-2.05%5/8/2024 (Confirmed)
Nutex Health Inc. stock logo
NUTX
Nutex Health
-$45.79M-$1.20N/AN/A-18.49%-45.58%-10.50%5/20/2024 (Estimated)

Latest HQY, MPLN, NUTX, and HALO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2024N/A
MultiPlan Co. stock logo
MPLN
MultiPlan
N/AN/AN/AN/AN/AN/A  
5/7/2024N/A
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
$0.64N/A-$0.64N/AN/AN/A  
3/28/2024Q4 2023
Nutex Health Inc. stock logo
NUTX
Nutex Health
N/A-$0.75-$0.75-$0.75N/A$69.67 million
3/19/2024Q4 2024
HealthEquity, Inc. stock logo
HQY
HealthEquity
$0.42$0.50+$0.08$0.70$258.56 million$262.39 million
2/29/2024Q4 2023
MultiPlan Co. stock logo
MPLN
MultiPlan
N/A-$0.06-$0.06-$0.07N/A$244.14 million    
2/20/2024Q4 2023
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
$0.77$0.75-$0.02$0.85$235.25 million$230.04 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
N/AN/AN/AN/AN/A
HealthEquity, Inc. stock logo
HQY
HealthEquity
N/AN/AN/AN/AN/A
MultiPlan Co. stock logo
MPLN
MultiPlan
N/AN/AN/AN/AN/A
Nutex Health Inc. stock logo
NUTX
Nutex Health
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
17.89
6.64
5.50
HealthEquity, Inc. stock logo
HQY
HealthEquity
0.43
4.76
4.76
MultiPlan Co. stock logo
MPLN
MultiPlan
2.65
1.16
1.16
Nutex Health Inc. stock logo
NUTX
Nutex Health
3.04
1.56
1.50

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
97.79%
HealthEquity, Inc. stock logo
HQY
HealthEquity
99.55%
MultiPlan Co. stock logo
MPLN
MultiPlan
87.15%
Nutex Health Inc. stock logo
NUTX
Nutex Health
5.32%

Insider Ownership

CompanyInsider Ownership
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
2.40%
HealthEquity, Inc. stock logo
HQY
HealthEquity
2.70%
MultiPlan Co. stock logo
MPLN
MultiPlan
8.20%
Nutex Health Inc. stock logo
NUTX
Nutex Health
48.48%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
373127.05 million124.01 millionOptionable
HealthEquity, Inc. stock logo
HQY
HealthEquity
3,12685.80 million83.48 millionOptionable
MultiPlan Co. stock logo
MPLN
MultiPlan
2,800644.37 million591.53 millionOptionable
Nutex Health Inc. stock logo
NUTX
Nutex Health
1,15049.72 million25.62 millionNot Optionable

HQY, MPLN, NUTX, and HALO Headlines

SourceHeadline
NUTEX HEALTH ANNOUNCES CHANGES TO ITS BOARD OF DIRECTORSNUTEX HEALTH ANNOUNCES CHANGES TO ITS BOARD OF DIRECTORS
prnewswire.com - April 22 at 5:30 AM
Nutex Health Hospitals Gain Community Recognition and Take Home Seven Patient Satisfaction Awards in Q1Nutex Health Hospitals Gain Community Recognition and Take Home Seven Patient Satisfaction Awards in Q1
prnewswire.com - April 16 at 5:30 AM
Nutex Health, Inc.: Nutex Health Provides Corporate UpdateNutex Health, Inc.: Nutex Health Provides Corporate Update
finanznachrichten.de - April 12 at 10:21 AM
NUTEX HEALTH PROVIDES CORPORATE UPDATENUTEX HEALTH PROVIDES CORPORATE UPDATE
prnewswire.com - April 12 at 5:30 AM
Nutex Health (NASDAQ:NUTX) Sees Large Volume IncreaseNutex Health (NASDAQ:NUTX) Sees Large Volume Increase
marketbeat.com - April 11 at 11:58 AM
Nutex Health (NASDAQ:NUTX) Hits New 12-Month Low at $1.03Nutex Health (NASDAQ:NUTX) Hits New 12-Month Low at $1.03
marketbeat.com - April 10 at 10:44 AM
NUTEX HEALTH OPENS FIRST HOSPITAL OF 2024 IN BELLEVUE, WISCONSINNUTEX HEALTH OPENS FIRST HOSPITAL OF 2024 IN BELLEVUE, WISCONSIN
finance.yahoo.com - April 8 at 8:47 AM
Nutex Health, Inc.: Nutex Health Announces 1-for-15 Reverse Stock SplitNutex Health, Inc.: Nutex Health Announces 1-for-15 Reverse Stock Split
finanznachrichten.de - April 5 at 9:16 AM
Why Is Nutex Health (NUTX) Stock Down 13% Today?Why Is Nutex Health (NUTX) Stock Down 13% Today?
investorplace.com - April 5 at 8:46 AM
NUTEX HEALTH ANNOUNCES 1-FOR-15 REVERSE STOCK SPLITNUTEX HEALTH ANNOUNCES 1-FOR-15 REVERSE STOCK SPLIT
prnewswire.com - April 5 at 5:30 AM
NUTX Stock Earnings: Nutex Health Misses Revenue for Q4 2023NUTX Stock Earnings: Nutex Health Misses Revenue for Q4 2023
investorplace.com - April 1 at 10:05 AM
Nutex Health, Inc.: Nutex Health Reports Fourth Quarter And Full Year 2023 Financial ResultsNutex Health, Inc.: Nutex Health Reports Fourth Quarter And Full Year 2023 Financial Results
finanznachrichten.de - March 29 at 7:06 AM
NUTEX HEALTH REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTSNUTEX HEALTH REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS
finance.yahoo.com - March 28 at 9:05 PM
3 Promising Penny Stocks You Can Pick Up for Less Than a Quarter3 Promising Penny Stocks You Can Pick Up for Less Than a Quarter
investorplace.com - March 18 at 8:49 PM
Nutex Health, Inc.: Nutex Health Announces Preliminary 2023 Headline Financials And Provides Update On The Timing Of Its 10-k FilingNutex Health, Inc.: Nutex Health Announces Preliminary 2023 Headline Financials And Provides Update On The Timing Of Its 10-k Filing
finanznachrichten.de - March 15 at 9:02 AM
NUTEX HEALTH ANNOUNCES PRELIMINARY 2023 HEADLINE FINANCIALS AND PROVIDES UPDATE ON THE TIMING OF ITS 10-K FILINGNUTEX HEALTH ANNOUNCES PRELIMINARY 2023 HEADLINE FINANCIALS AND PROVIDES UPDATE ON THE TIMING OF ITS 10-K FILING
prnewswire.com - March 15 at 5:00 AM
Nutex Health Stock (NASDAQ:NUTX), Analyst Ratings, Price Targets, PredictionsNutex Health Stock (NASDAQ:NUTX), Analyst Ratings, Price Targets, Predictions
benzinga.com - February 23 at 10:48 PM
Nutex Healths Medicare Advantage membership doublesNutex Health's Medicare Advantage membership doubles
msn.com - February 5 at 8:17 AM
NUTEX HEALTH ANNOUNCES OVER 100% INCREASE IN MEDICARE ADVANTAGE ENROLLMENTNUTEX HEALTH ANNOUNCES OVER 100% INCREASE IN MEDICARE ADVANTAGE ENROLLMENT
finance.yahoo.com - February 5 at 8:17 AM
Nutex Health, Inc.: Nutex Health Announces Streamlined Strategic PlanNutex Health, Inc.: Nutex Health Announces Streamlined Strategic Plan
finanznachrichten.de - January 31 at 10:02 AM
NUTEX HEALTH ANNOUNCES YORKVILLE PAYOFF AND STREAMLINED STRATEGIC PLANNUTEX HEALTH ANNOUNCES YORKVILLE PAYOFF AND STREAMLINED STRATEGIC PLAN
finance.yahoo.com - January 30 at 10:17 AM
Nutex Prices Direct Offering, Stock Plummets In Pre-marketNutex Prices Direct Offering, Stock Plummets In Pre-market
markets.businessinsider.com - January 23 at 4:35 PM
Nutex Health Announces Pricing of $10.0 Million Registered Direct Offering of Common Stock and WarrantsNutex Health Announces Pricing of $10.0 Million Registered Direct Offering of Common Stock and Warrants
finance.yahoo.com - January 23 at 4:35 PM
Nutex Health Inc.s (NASDAQ:NUTX) top owners are retail investors with 47% stake, while 43% is held by insidersNutex Health Inc.'s (NASDAQ:NUTX) top owners are retail investors with 47% stake, while 43% is held by insiders
finance.yahoo.com - January 18 at 9:51 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Halozyme Therapeutics logo

Halozyme Therapeutics

NASDAQ:HALO
Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.
HealthEquity logo

HealthEquity

NASDAQ:HQY
HealthEquity, Inc. provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts. It also provides investment platform; and online-only automated investment advisory services through Advisor, a Web-based tool. In addition, the company offers flexible spending accounts; health reimbursement arrangements; and Consolidated Omnibus Budget Reconciliation Act continuation services, as well as administers pre-tax commuter benefit programs. It serves clients through a direct sales force; benefits brokers and advisors; and a network of health plans, benefits administrators, benefits brokers and consultants, and retirement plan record-keepers. HealthEquity, Inc. was incorporated in 2002 and is based in Draper, Utah.
MultiPlan logo

MultiPlan

NYSE:MPLN
MultiPlan Corporation, together with its subsidiaries, provides data analytics and technology-enabled cost management, payment, and revenue integrity solutions to the healthcare industry in the United States. The company offers analytics-based services that reduce medical costs, through data-driven algorithms and insights that detect claims over-charges and negotiate or recommend reimbursement; and network-based services that provide contracted discounts with healthcare providers, as well as outsourced network development and management services. It provides payment and revenue integrity services, such as identifying and removing improper and unnecessary charges paid during the claim, as well as services to identify and help restore and preserve underpaid premium dollars. In addition, the company offers data and decision science services including a suite of solutions that apply modern methods of data science to produce descriptive, predictive, and prescriptive analytics that drive optimized benefit plan design, support decision-making, improve clinical outcomes, and reduce the total cost of care; and business-to-business healthcare payments and other services. It serves national and regional insurance companies, Blue Cross and Blue Shield plans, provider-sponsored and independent health plans, TPAs, self-insured health plans, property and casualty insurers, bill review companies, and other companies involved in the claim adjudication process. MultiPlan Corporation was founded in 1980 and is headquartered in New York, New York.
Nutex Health logo

Nutex Health

NASDAQ:NUTX
Nutex Health Inc. operates as a network of micro-hospitals. It operates through three segments: Hospital, Population Health Management, and Real Estate. The Hospital segment develops and operates a network of micro-hospitals, specialty hospitals and hospital outpatient departments which offers 24/7 care. The Population Health Management segment establishes and operates independent physician associations; and offers a cloud-based platform for healthcare organizations to provide value-based care and population health management. The Real Estate segment leases land and hospital building. It also provides healthcare and facility management services; and healthcare billing, coding, and collection services. In addition, the company offers healthcare services, including emergency room care, inpatient care, and behavioral health, as well as onsite imaging, such as CT scan, X-ray, MRI, ultrasound, etc.; certified and accredited laboratories; and onsite inpatient pharmacies. The company was founded in 2011 and is based in Houston, Texas.